This strategy can be applied to the usage of the modern day immunotherapies such as checkpoint inhibitor immunotherapies versus targeted therapies such as BRAF/MEK inhibitors for melanoma patients before treatment [1]. This evidence concerns the gene MAP2K7 and melanoma.